|Enanta Pharmaceuticals, Inc.|
500 Arsenal Street
United States - Map
Enanta Pharmaceuticals, Inc., a biotechnology company, is engaged in the development of small molecule drugs for the infectious disease field. Its product portfolio includes ABT-450, a protease inhibitor that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV); ABT-493, a next-generation protease inhibitor for HCV infection; EDP-239, an NS5A inhibitor for HCV infection; Cyclophilin inhibitor, which are in preclinical development stage for HCV infection treatment; and Nucleotide Polymerase inhibitor program for HCV infection. The company also develops Bicyclolide antibiotic products comprising EDP-788 for the treatment of methicillin-resistant Staphylococcus aureus bacteria. It has collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc.; and AbbVie Inc. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
|Enanta Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Feb 1, 2014 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 7; Compensation: 5.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Jay R. Luly Ph.D.,
Chief Exec. Officer, Pres and Director
|Mr. Paul J. Mellett Jr.,
Chief Financial Officer, Principal Accounting Officer and Sr. VP of Fin. & Admin.
|Dr. Yat Sun Or Ph.D.,
Chief Scientific Officer and Sr. VP of R&D
|Dr. Timothy D. Ocain Ph.D.,
Sr. VP of New Product Strategy and Devel.
|Mr. Nathaniel S. Gardiner ,
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|